Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer

Banibrata Sen¹, Shaohua Peng¹, Babita Saigal¹, Michelle D. Williams¹,², and Faye M. Johnson¹,³*

¹Departments of Thoracic/Head and Neck Medical Oncology and ²Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; ³The University of Texas Graduate School of Biomedical Sciences at Houston, Texas

Running title: c-Met mediates resistance to c-Src inhibition

*Correspondence: Department of Thoracic/Head and Neck Medical Oncology, Unit 432, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030-4009; tel: 713-792-6363; fax: 713-792-1220; e-mail: fmjohns@mdanderson.org.

**Key words:** c-Src, c-Met, head and neck cancer

This work was supported by the Head and Neck SPORE (P50 CA097007) and the generous donations of cancer patients and their families. FACS was funded by National Cancer Institute grant CA 16672.
Translational Relevance

Although invasion is important in the pathophysiology of many cancers, local invasion is critical in head and neck cancers as a determinant of both morbidity and mortality, as it is associated with poorer locoregional control and decreased survival. Cancer therapy that both induces significant apoptosis and decreases invasion would be ideal for head and neck cancer. Because c-Src inhibition leads to profoundly diminished invasion with only moderate effects on survival and proliferation, we sought to identify pathways leading to cytotoxicity downstream of c-Src. Here we demonstrate that sustained c-Met activation mediates cell survival following c-Src inhibition. We investigated the biological importance of this interaction and discovered that c-Src and c-Met inhibition were synergistic. Given that both c-Src and c-Met inhibitors are in clinical use, our studies are immediately relevant for human cancer treatment.
ABSTRACT

Purpose: c-Src inhibition in cancer cells leads to an abrogation of invasion but a variable effect on apoptosis. The pathways downstream of c-Src promoting survival are not well-characterized. Because cancer therapy that both decreases invasion and induces significant apoptosis would be ideal, we sought to characterize the mechanisms of resistance to c-Src inhibition.

Experimental Design: c-Src was inhibited in a panel of oral cancer cell lines and subsequent survival and signaling measured. The interactions between c-Src and c-Met were evaluated using immunoprecipitation and an in vitro kinase assay. Cytotoxicity was measured and the Chou-Talalay combination index calculated. An orthotopic model of oral cancer was used to assess the effects of c-Met and c-Src inhibitors.

Results: Inhibition of c-Src resulted in c-Met inhibition in sensitive cells lines, but not in resistant cell lines. Isolated c-Met was a c-Src substrate in both sensitive and resistant cells, but there was no interaction of c-Src and c-Met in intact resistant cells. To examine the biological consequences of this mechanism, we demonstrated synergistic cytotoxicity, enhanced apoptosis, and decreased tumor size with the combination of c-Src and c-Met inhibitors.

Conclusions: Sustained c-Met activation can mediate resistance to c-Src inhibition. These data suggest that the differences between c-Met and c-Src signaling in sensitive and resistant cells are due to distinct factors promoting or inhibiting interactions, respectively, rather than to intrinsic structural changes in c-Src or c-Met. The synergistic cytotoxic effects of c-Src and c-Met inhibition may be important for the treatment of head and neck cancers.
Introduction

All epithelial tumors pose formidable challenges in clinical practice, but the anatomy of tumors in the head and neck region makes them particularly difficult to treat. Approximately 45,000 new cases of head and neck cancer are diagnosed in the United States each year, and the estimated worldwide incidence is 500,000 (1). The incidence and survival statistics are only half of the story, however; cancer- and treatment-induced distortions of anatomy and physiology have a profound impact on important functions such as eating, speaking, and hearing, and distortions in facial appearance contribute to social isolation in survivors. Although novel approaches have improved locoregional control in patients with advanced head and neck squamous cell carcinoma (HNSCC), locoregional and distant recurrence remains common and is almost always fatal. Thus, there is a great need to improve systemic therapy for patients with these tumors in order to increase cure rates and reduce morbidity.

The most successful targeted molecular therapeutic approach is inhibition of oncogene targets, particularly tyrosine kinases. One potential oncogene target in HNSCC is the c-Src family of nonreceptor tyrosine kinases (SFKs) (2, 3). Aberrant activation of c-Src has been demonstrated in numerous epithelial tumors, including HNSCC. c-Src regulates multiple signaling cascades that control diverse biological processes, and its inhibition in cancer cells can lead to reduced anchorage-independent growth, proliferation, survival, invasion, migration, metastasis, and tumor vascularity (2). In epithelial cancers, however, several researchers have observed that, while c-Src inhibition decreases migration and invasion, it has little effect on proliferation or apoptosis (4-6). In 10 of 12 colon cancer cell lines, complete inhibition of c-Src activity did not affect cell proliferation, although it did inhibit adhesion and migration (7). Similarly, c-Src
inhibition in pancreatic cancer cells had no effect on cell cycle progression but completely inhibited migration and angiogenesis (8). We demonstrated that c-Src inhibition resulted in a universal and profound reduction of invasion and migration of all HNSCC cell lines, but produced cytotoxicity in only 4 of 9 HNSCC cell lines (9, 10). Clearly, c-Src can mediate distinct biological processes independently. This may be accomplished by differential effects of c-Src on its multiple downstream substrates.

Although the molecular mechanisms that mediate c-Src’s effects on migration have been well described (11), those that mediate proliferation and survival are less well defined. c-Src can mediate its effects on proliferation and survival via interactions with growth factor receptors as well as the ERK1/2, JAK/STAT, and phosphoinositide 3-kinase (PI3K) pathways. c-Src may activate the PI3K pathway by 3 distinct mechanisms: direct interaction and phosphorylation of AKT (12, 13); interaction and activation of PI3K (14, 15); and reversal of PTEN activity (16).

Since local invasion is a critical determinant of both morbidity and mortality for HNSCC, systemic therapy that both decreases local invasion and induces significant cancer cell cytotoxicity would be ideal. Given that c-Src inhibition already results in a significant decrease in invasion, we sought in this study to understand the mechanisms underlying the effects of c-Src inhibition on cancer cell survival. We studied several signaling pathways known to interact with c-Src and discovered a correlation between the biological effects of c-Src inhibition and downstream signaling effects on the receptor tyrosine kinase c-Met. c-Met is known to signal both upstream and downstream from c-Src. It mediates resistance to epidermal growth factor receptor (EGFR) inhibition in lung cancer (17, 18) and c-Src inhibition in gastric cancer cell
lines (19). Activation of c-Met by its ligand hepatocyte growth factor (HGF) is observed in
HNSCC cell lines and tumors (20, 21); this activation stimulates migration and invasion and
inhibits apoptosis of HNSCC cells (20, 22-25). We hypothesized that persistent c-Met activation
following c-Src inhibition mediates resistance to apoptosis and cell cycle arrest.
Materials and Methods

Materials

Antibodies used in the Western blot analysis included c-Met (Santa Cruz Biotechnology, Santa Cruz, CA); pSFK (Y416), pSTAT3 (Y705), pPDK1 (S241), pan-AKT, pAKT (S473), and pMet (Y1234/1235 and Y1349) (Cell Signaling Technology, Beverly, MA); HGF and pMet (Y1365) (Abcam, Cambridge, MA), pMet (Y1003) (BD Bioscience, Bedford, MA), and beta-actin (Sigma Chemical, St. Louis, MO). For immunoprecipitation studies, agarose-conjugated c-Src antibody was obtained from Calbiochem (La Jolla, CA) and agarose-conjugated c-Met antibody from Santa Cruz Biotechnology. Dasatinib was purchased from The University of Texas MD Anderson Cancer Center pharmacy and prepared as a 10 mM stock solution in dimethyl sulfoxide (DMSO). PHA665752 and PF02341066 (crizotinib) were provided by Pfizer Pharmaceuticals (New London, CT) and prepared as a 10 mM stock solution in DMSO. Human HGF Quantikine ELISA was purchased from R&D system (Minneapolis, MN).

Cell culture

Human HNSCC cell lines were obtained from Dr. Jeffrey Myers (MD Anderson Cancer Center, Houston, Texas) and maintained as described previously (10). Short tandem repeat profiling was performed on cellular DNA submitted to the Johns Hopkins University Fragment Analysis Core facility (Baltimore, MD). All cell lines were validated by cross-comparing their allelic short tandem repeat patterns, generated with the PowerPlex 1.2 platform (Promega, Madison, WI), to the American Type Culture Collection repository database. Cells were passed in culture no more than 6 months after being thawed from authenticated stocks.
MTT assay

Cytotoxicity was assessed by the MTT assay as described elsewhere (9). For each experimental condition, at least 4 wells were treated. Cytotoxic effects and the combination index were calculated by using the Chou-Talalay equation, which takes into account both the potency (IC$_{50}$) and shape of the dose-effect curve (26-28), using CalcuSyn software (Biosoft, Ferguson, MO).

Cell cycle and apoptosis assays

For the cell cycle analysis, cells were harvested, fixed, and stained with propidium iodide as previously described (29). DNA content was analyzed on a cytofluorimeter by fluorescence-activated cell sorting analysis (FACS) (FACScan; Becton Dickinson, San Jose, CA) using ModFit software (Verity Software House, Turramurra, New South Wales, Australia). To analyze apoptosis, cells were fixed and subjected to terminal deoxynucleotidyl transferase biotin-dUTP nick-end labeling (TUNEL) staining according to the manufacturer’s protocol (APO-BRDU kit; Phoenix Flow Systems, Inc., San Diego, CA) as described previously (29).

Transfection with siRNA

Cells were harvested, washed, and suspended (10$^6$ cells/100 mL) in Nucleofector-V solution (Amaxa, Gaithersburg, MD), and siRNA (200 pmol/100 mL) was added. Cells were electroporated (U-31 Nucleofector program, Amaxa) and then immediately diluted with prewarmed 500 μL Dulbecco’s modified essential medium and plated onto 6-well plates. The medium was changed after 16 h. All c-Src and c-Met siRNAs were predesigned as sets of 4 independent sequences (siGENOME SMARTpool, Dharmacon Inc., Lafayette, CO). Controls included cells transfected with a nontargeting (scrambled) siRNA and mock transfected cells.
(i.e., no siRNA).

**Immunoprecipitation and Western blot analysis**

Western blot analysis and immunoprecipitation were performed as previously described (9, 29). Briefly, cells were subjected to lysis on ice and lysates centrifuged at 15,000 rpm for 5 min at 4°C. For the immunoprecipitation, equal amounts of the protein cell lysate supernatant (500 mg) were precleared with Protein A and G Sepharose beads (Invitrogen Corporation, Carlsbad, CA). The precleared lysate was incubated with 5 μg of either the agarose-conjugated c-Met or c-Src primary antibody overnight. The immunoprecipitates containing agarose beads were washed 4 times with immunocomplex wash buffer (50 mmol/L Tris-HCl [pH 7.5], 100 mmol/L NaCl, 1% Triton X-100, 1 mmol/L EGTA, 1 mmol/L EDTA, 1% glycerol, 20 μg/mL leupeptin, 10 μg/mL aprotinin, 1 mmol/L phenylmethylsulfonyl fluoride, 1 mmol/L sodium vanadate) and boiled with 1× sample buffer for 5 min. For both the immunoprecipitation and the Western blot, equal protein aliquots were resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), transferred to nitrocellulose membranes, immunoblotted with primary antibody, and detected with horseradish peroxidase–conjugated secondary antibody (Bio-Rad Laboratories, Hercules, CA) and ECL reagent (Amersham Biosciences, Piscataway, NJ).

**In vitro kinase assay**

In *vitro* kinase assays were performed as previously described (29). Briefly, Tu167 and Osc-19 cells were incubated with 100 nM dasatinib, DMSO (vehicle control), or 2 μM PHA665752 for 7 h before cells were subjected to lysis, and c-Met or c-Src was immunoprecipitated as described in the previous paragraph. The immunocomplexes were washed and resuspended in a kinase...
assay reaction buffer that contained 15 microCi \( [\gamma^{32}\text{P}]\text{ATP} \). During the kinase assay, 100 nM dasatinib or 2 \( \mu \text{M} \) PHA665752 was added to their respective samples. The reaction was terminated after 30 min at room temperature with sample buffer, and boiled immunocomplexes were separated by 8% SDS-PAGE. Radiolabeled proteins were detected by autoradiography. When c-Src and c-Met were assayed together, both were independently immunoprecipitated and then the immunoprecipitated fractions were combined in the kinase assay.

**Orthotopic nude mouse models**

All animal procedures were done in accordance with the Institutional Animal Care and Use Committee’s policies. Osc-19-LN5-Rluc cells were injected submucosally into the tongues of athymic nude mice as previously described (30). Mice that developed tumors were randomized into four treatment groups: vehicle alone (control), crizotinib [PF02341066 (20 mg/kg/day)] alone, dasatinib alone (20 mg/kg daily), or dasatinib plus crizotinib; all agents were administered by oral gavage. Tumor volume was estimated by direct measurement using calipers and in vivo bioluminescence imaging on days 1, 5, and 9 as described (30). Mice were sacrificed on day 10 and tumors were dissected. Mice were examined for regional and distant metastases. The tongue tumors were homogenized and subjected to Western blotting.
RESULTS

Oral squamous carcinoma cell lines have diverse sensitivities to SFK inhibition

We used a panel of 11 independent, authenticated HNSCC cell lines derived from the oral cavity to measure the effects of SFK inhibition on cytotoxicity, proliferation, and survival. All cell lines were incubated with the SFK inhibitor dasatinib, and cytotoxicity was measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Median inhibitory concentrations (IC\textsubscript{50}) for those cell lines ranged from 45 nM to >5 μM (Table 1). We also determined the effect of SFK inhibition on cell cycle progression and apoptosis in a panel of 7 lines with diverse sensitivities to dasatinib (Fig. 1). Dasatinib did not affect proliferation or survival in resistant cell lines (IC\textsubscript{50} values >100 nM) but affected both qualities in 2 of 3 sensitive lines.

Prolonged exposure to SFK inhibition leads to acquired resistance

To study resistance to SFK inhibition in an isogenic setting, the sensitive cell line Tu167 was incubated with increasing concentrations of dasatinib. Ultimately, two cell lines (Tu167R1 and Tu167R2) were able to grow in 300 nM dasatinib with doubling times similar to that of the parent cell line. Both cell lines had a significantly higher IC\textsubscript{50} value than Tu67 (Table 1) and did not undergo cell cycle arrest or apoptosis upon exposure to dasatinib (Fig. 1).

Inhibition of SFK results in c-Met inhibition in HNSCC cells that are sensitive to SFK inhibition

To determine the mechanisms underlying SFK resistance, we investigated signaling pathways that cooperate with or are downstream of SFK in epithelial malignancies. We observed that SFK
inhibition led to inhibition of c-Met in sensitive cell lines (Fig. 2A, B, C) but not in resistant lines (Fig. 2A, B, C, D). Moreover, the PI3K pathway (AKT or PDK1) was inhibited in cell lines that underwent apoptosis (Tu167, PCI-13) when exposed to dasatinib (Fig. 2), while the effects on the mitogen-activated protein kinase pathway, as measured by pERK1/2, were variable (data not shown). Surprisingly, we also observed that c-Met and AKT were not inhibited even at elevated concentrations of dasatinib (200 nM) in Tu167R2, whereas dasatinib did inhibit SFKs in this isogenic resistant cell line (Fig. 2D). Dasatinib did not inhibit SFK in Tu167R1 even at elevated concentrations (200 nM), demonstrating that direct resistance of the target (i.e., SFK) to the drug is the mechanism for these cells’ insensitivity to the cytotoxic effects of dasatinib (Fig. S1). Thus we did not further study c-Src and c-Met interactions in Tu167R1.

**Specific inhibition of c-Src leads to c-Met inhibition in sensitive HNSCC cells**

To determine whether the inhibition of c-Met was due to inhibition of SFKs or to an off-target effect of dasatinib, c-Src was specifically depleted by using small interfering RNA (siRNA). In sensitive cells, c-Src knockdown led to substantial inhibition of c-Met, while in resistant cells, c-Src depletion did not affect c-Met activation (Fig. 2E). Similar to the results with dasatinib, specific c-Src knockdown led to inhibition of AKT in sensitive cells and not in resistant cell lines.

**Baseline expression or activation of c-Src or c-Met did not predict biological response to SFK inhibitors**

We hypothesized that cell lines with high basal levels of activated c-Src or c-Met would be more likely to be sensitive to SFK inhibition. We examined the basal expression and activation of
these proteins in 8 HNSCC lines (Fig. S2) that had previously been characterized (Table 1) and found no such correlation.

c-Met is a c-Src substrate in both sensitive and resistant cell lines
To determine if c-Met is a direct c-Src substrate, we incubated isolated c-Met, c-Src, or both from resistant (Osc-19) and sensitive (Tu167) cell lines and measured kinase activity by an in vitro kinase assay. As expected, dasatinib and c-Met inhibitor PHA665752 inhibited c-Src and c-Met kinase activity respectively and specifically (Fig. 3A-B, lanes 1–6). In both cell lines, inhibition of c-Src led to decreased expression of phosphorylated c-Met (Fig. 3A-B, lanes 7 vs. 8), but the inhibition of c-Met did not affect expression of phosphorylated c-Src (Fig. 3A-B, lanes 7 vs. 9). Furthermore, in the presence of PHA665752 and c-Src, c-Met was phosphorylated, confirming that c-Met is a direct c-Src substrate (Fig. 3A-B, lane 9) and acts as a downstream signaling molecule for c-Src kinase.

c-Src and c-Met interactions are distinct in HNSCC cell lines
Although the in vitro kinase assay demonstrated that c-Met is a c-Src substrate in both sensitive and resistant cell lines, c-Src knockdown or inhibition reduced c-Met activation in some HNSCC cell lines but not others. These data suggest that there is no intrinsic change in the c-Src or c-Met molecules, but that the interaction between c-Src and c-Met differs in sensitive and resistant intact cells. To investigate this possibility, we immunoprecipitated c-Met or c-Src from sensitive and resistant cells (Fig. 3C). In Tu167 cells, an interaction between c-Src and c-Met was demonstrated by the immunoprecipitation of both c-Src and c-Met. No such interaction was demonstrated in resistant cells.
The effect of SFK inhibition on c-Met is not mediated via the release of ligand

We examined whether the release of HGF mediates SFK’s effect on c-Met activation. In a panel of 6 HNSCC cell lines with diverse sensitivities to dasatinib (Tu167, Tu167R2, PCI13, Osc19, Tu138 and TR146) we did not detect HGF secretion by ELISA into the cell culture medium in control or dasatinib-treated cells (up to 48 h incubation). Likewise, cellular levels of HGF did not change following dasatinib treatment in any of these cell lines (Fig. 4A). Exogenous HGF led to the activation of c-Met on 4 distinct sites (Fig. 4A). In sensitive cells, dasatinib inhibited the phosphorylation of Y1234/1235 (activation loop), Y1365 (morphology/motility), and Y1349 (Gab1 binding) in both the presence and absence of exogenous HGF but did not affect Y1003 (ubiquitination). All cell lines expressed the adaptor protein Gab1.

EGFR contributes to c-Met activation in resistant cell lines

Previous reports have demonstrated cross talk between EGFR and c-Met. To determine if EGFR contributes to c-Met activation in HNSCC, cells were incubated with the EGFR inhibitor erlotinib, dasatinib, or a combination of both agents (Fig. 4B). In all cell lines tested, EGFR inhibition did lead to c-Met inactivation with no effect of SFK activation. The combination of erlotinib and dasatinib resulted in a cooperative effect on c-Met activation and a significant decrease in AKT activation in the resistant cell lines. Likewise, our previous work demonstrated that dasatinib and erlotinib are additive in HNSCC cells in vitro (9).

SFK and c-Met inhibitors show synergistic effect on HNSCC cell viability in vitro and in vivo
Given that c-Met is not inhibited in cell lines that are resistant to SFK inhibition, we hypothesized that persistent c-Met activation may mediate this resistance. To test this, a panel of 7 HNSCC cell lines with diverse sensitivities to SFK inhibition was incubated with dasatinib, PHA665752, or the combination, and cytotoxicity was measured by the MTT assay. We also calculated the combination index for the drug combination (Table 2). A combination index value of less than 1 indicates synergy; a value equal to 1 indicates an additive effect; and a value greater than 1 indicates antagonism. Representative cytotoxicity data are shown in Fig. 5A and 5B.

None of the cell lines demonstrated the extreme sensitivity to PHA-665752 that occurs in cells with amplified c-Met (IC50 < 100 nM) (31). However, 3 of the 7 lines demonstrated IC50 values that were less than or close to 2.5 μM, a concentration at which we observed significant inhibition of c-Met (Fig. S3); inhibition of c-Met was incomplete at a concentration of 1 μM (unpublished data). As hypothesized, the combination of c-Met and SFK inhibition was synergistic in the dasatinib-resistant cell lines. Consistent with the cytotoxicity data, this finding shows that the combination resulted in significantly more apoptosis than either agent alone (Fig. 5C). Surprisingly, the combination was also synergistic in the dasatinib-sensitive (Tu167, TR146) and intermediate (UMSCC14a) cell lines, suggesting that inhibition of the residual c-Met activation following SFK inhibition was adequate to enhance cytotoxicity (Table 2).

As expected, PHA665752 inhibited c-Met and dasatinib inhibited c-Src in HNSCC cell lines (Fig. 5D). We also examined the effect of these inhibitors on activated ErbB3 because ErbB3 can mediate c-Met’s effects in EGFR inhibitor-resistant non–small cell lung cancer (NSCLC) cell
lines (17). However, we did not find any consistent effect of c-Met or SFK inhibition on activated ErbB3. In most of these cell lines, the combination led to decreased signaling through the PI3K pathway (PDK1 or AKT).

Consistent with our in vitro data, we also observed that the combination of c-Src and c-Met inhibition reduced tumor size in vivo (Fig. 5E, S4). In the in vivo studies, we utilized crizotinib due to the poor oral bioavailability of PHA665752. The single agents alone did not significantly affect tumor size. Western blotting of tumors confirmed that the drugs affected their targets (Fig. S5). There was a statistically non-significant trend toward decreased nodal metastasis in mouse treated with the combination (3 of 20 nodes examined contained tumor, 15%) compared to control (7/28, 25%) or single agents [dasatinib (8/27, 30%) or crizotinib (4/21, 19%)]. The number of mice with nodal metastasis ranged from 42-56%.

We previously observed that c-Src inhibition led to a universal inhibition of invasion and migration independent of its effects on apoptosis (10). Both PHA665752 and dasatinib inhibited invasion and migration; the combination was more effective than the single agents (Fig. S6). The effect was independent of the effects of either drug on cytotoxicity.

**Specific depletion of c-Src and c-Met in HNSCC cell lines**

To determine if the enhanced cytotoxic effects of dasatinib and PHA665752 were due to specific effects of the drugs on c-Src and c-Met, respectively, we specifically knocked down c-Src and c-Met with siRNA and measured the surviving cells by using an MTT assay (Fig. 6, S7). In both Osc-19 and Tu167 cells, c-Src depletion alone led to a decrease of about 25% in cell number,
and c-Met depletion alone led to a decrease of about 15% in cell number ($P<0.05$ vs. control or scrambled siRNA). Consistent with the pharmacologic data (Table 2), the results show that the combination was more effective than either of the single siRNAs, with reductions in cell number of 36% for Tu167 and 54% for Osc-19 ($P<0.05$ vs. control or scrambled or c-Src alone or c-Met alone). As we previously observed (29), the effect of c-Src knockdown was markedly less cytotoxic than SFK inhibition with dasatinib, probably because of 3 factors: dasatinib inhibits all SFKs (not just c-Src), dasatinib is a much more effective c-Src inhibitor than siRNA, and dasatinib likely has off-target effects that contribute to its cytotoxicity (32).
DISCUSSION

In this study we sought to identify pathways leading to cytotoxicity downstream of c-Src inhibition and demonstrated that sustained c-Met activation mediates cell survival following c-Src inhibition. We observed a correlation between the effects of c-Src inhibition on c-Met activity and its effects on apoptosis. While c-Met and c-Src isolated from sensitive cells and from resistant cells behave similarly, the interaction between c-Met and c-Src in intact sensitive and resistant cell lines differs. This implies that there are factors promoting c-Src/c-Met interaction in sensitive cells and/or factors inhibiting such interaction in resistant cells; this will be tested in our future studies. We speculate that these factors are adaptor proteins that can affect c-Src or c-Met localization and/or protein-protein binding and interaction. We investigated the biological consequences of this interaction and discovered that SFK inhibitor dasatinib and c-Met inhibitor PHA-665752 have synergistic cytotoxic and proapoptotic effects and that the combination of c-Src and c-Met siRNA has enhanced cytotoxicity. c-Met inhibition alone (by siRNA or PHA665752) had a statistically significant but minimal effect on cytotoxicity, demonstrating that c-Src mediates some of its effects independently of c-Met. Together these data support a model in which c-Src and c-Met cooperate to maintain cell survival in sensitive HNSCC cells. In resistant cell lines, alternative pathways must exist that allow cell survival despite complete c-Src and c-Met inhibition (Fig. S8).

We did not expect there to be only a single mechanism of resistance to c-Src inhibition. This situation is analogous to resistance of cancers to targeted agents and to cytotoxic chemotherapy drugs, which is mediated by diverse mechanisms (33). For example, resistance to EGFR inhibitors in lung cancer can be mediated by additional mutations in EGFR (T790M),
amplification of c-Met (17), activation of the insulin growth factor receptor (34), and other undefined mechanisms. Correspondingly, an unbiased approach to identifying proteins with significant changes in tyrosine phosphorylation upon c-Src activation identified 136 proteins with increased tyrosine phosphorylation, including c-Met (35). These data are supported by the finding that gastric cell lines that express c-Met are resistant to SFK inhibition–induced apoptosis (19). We also demonstrated that the reactivation of STAT3 following sustained c-Src inhibition may contribute to resistance to c-Src inhibition (29). Even though alternative mechanisms may exist, however, the combination of c-Met and c-Src inhibitors was synergistic in all cell lines tested, suggesting that this is a rational combination for future clinical studies.

Cross-talk between c-Met and c-Src has been demonstrated in other epithelial tumors and often involves Her family members. Serum starvation of bladder cancer cell lines leads to release of growth factors that activate EGFR, which subsequently activates c-Met in a c-Src–dependent manner. This process is not dependent upon ligand-mediated activation of c-Met, rather the c-Met is activated by c-Src (36). Likewise, c-Met can be activated by EGFR in human hepatoma cell lines (37), anaplastic thyroid cancer cells (38), and lung cancer (39), but the role of c-Src in these systems was not investigated. In a separate study, pharmacologic inhibition of SFKs led to decreased levels of phosphorylated c-Met in 4 of 5 colon cancer cell lines, but the mechanism was not defined (40).

Signaling between c-Src and c-Met can be bidirectional. Activation of c-Met by HGF in breast cancer cell lines leads to the interaction of c-Src and c-Met and subsequent activation of c-Src. The kinase activity of c-Src is required for HGF–induced cell motility and anchorage-
independent growth (41). In our study, however, the inhibition of c-Met did not affect c-Src activation in intact cells and HGF was not affected by dasatinib. Likewise, c-Src was not a direct c-Met substrate. These differences may be due to the difference in cell type (HNSCC vs. breast) or the different approaches employed to manipulate c-Met activation (i.e., ligand stimulation vs. kinase inhibition). Moreover, c-Met inhibition alone leads to cytotoxicity and AKT inhibition in some cancer cell lines (42) and in HNSCC in vivo (21), but in our HNSCC in vitro, this was not observed.

In lung cancer cell lines, c-Met can mediate resistance to EGFR inhibition. When NSCLC cell lines with activating EGFR mutations were incubated with increasing concentrations of the EGFR inhibitor gefitinib, the resulting gefitinib-resistant NSCLC cells had amplified c-Met and persistent activation of ErbB3 and AKT following exposure to gefitinib. Although these cells were resistant to both gefitinib and PHA665752, the combination resulted in growth inhibition and suppression of AKT and ErbB3 phosphorylation. We also observed suppression of ErbB3 phosphorylation with the combination of dasatinib and PHA665752, but in only 1 of 6 cell lines tested (Tu138). c-Src inhibition had no observed effect on activated EGFR in HNSCC cells (9). EGFR inhibition did lead to c-Met inhibition in resistant cell lines. In NSCLC cell lines, activation of ErbB3 by c-Met was not c-Src dependent (17). Similarly, in breast cancer cell lines, c-Met activation can mediate EGFR resistance, but through a mechanism that is distinct from that of NSCLC. In breast cancer cells, c-Met activation leads to EGFR kinase-independent phosphorylation of EGFR via a c-Src–dependent mechanism. Thus, despite the presence of an EGFR kinase inhibitor, EGFR can still be phosphorylated and contribute to cell growth (43). Interestingly, engagement of EGFR signaling can mediate resistance of NSCLC cells to c-Met
inhibition *in vitro*, further demonstrating an intimate link between these two pathways in lung cancer (44).

Any study using pharmacological agents is limited by drug specificity. Although PHA-665752 did drastically reduce the IC$_{50}$ for dasatinib, it brought this value into a range that we consider SFK specific ($<100$ nM) in only 2 of the 5 dasatinib-resistant cell lines (Osc-19 and UMSCC14a), suggesting that resistance in these lines may be “driven” by other signaling pathways that may include the JAK-STAT signaling axis (29). However, the enhanced cytotoxicity observed with the combination of c-Src and c-Met siRNA does demonstrate that these 2 specific pathways can cooperate to contribute to cell survival. At the concentrations we used, PHA665752 inhibits c-Met, Ron, Flk-1, and c-Abl (42) and dasatinib inhibits c-Abl, PDGFR, Btk, EphA2, and others (32, 45, 46).

In conclusion, this study offers new insights into the interaction of c-Src and c-Met in HNSCC cells. In cells that were sensitive to SFK inhibition, c-Met was a c-Src substrate and the 2 proteins interacted. This interaction did not occur in resistant cell lines even though the isolated c-Met was a c-Src substrate. This is the first study to demonstrate a potential mechanism by which c-Met activation can mediate resistance to SFK inhibition in only a subpopulation of cancer cells. The synergistic effects of SFK and c-Met inhibition may have important clinical implications for the treatment of HNSCC.
References


### Tables

#### Table 1: IC$_{50}$ Values for Dasatinib in HNSCC Cell Lines

<table>
<thead>
<tr>
<th>Cell Line</th>
<th>Source</th>
<th>IC$_{50}$ (nM)</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tu167</td>
<td>Oral cavity, floor of mouth</td>
<td>45 ± 8</td>
<td>Sensitive</td>
</tr>
<tr>
<td>TR146</td>
<td>Oral cavity</td>
<td>67 ± 2</td>
<td>Sensitive</td>
</tr>
<tr>
<td>PCI-24</td>
<td>Oral cavity, tongue</td>
<td>53 ± 14</td>
<td>Sensitive</td>
</tr>
<tr>
<td>PCI-13</td>
<td>Oral cavity</td>
<td>96 ± 15</td>
<td>Sensitive</td>
</tr>
<tr>
<td>HN5</td>
<td>Oral cavity, tongue</td>
<td>140 ± 79</td>
<td>Intermediate</td>
</tr>
<tr>
<td>UMSCC47</td>
<td>Oral cavity, tongue</td>
<td>160 ± 34</td>
<td>Intermediate</td>
</tr>
<tr>
<td>UMSCC2</td>
<td>Oral cavity, alveolar ridge</td>
<td>180 ± 37</td>
<td>Intermediate</td>
</tr>
<tr>
<td>UMSCC15A</td>
<td>Oral cavity</td>
<td>186 ± 15</td>
<td>Intermediate</td>
</tr>
<tr>
<td>OSC19</td>
<td>Oral cavity</td>
<td>312 ± 36</td>
<td>Resistant</td>
</tr>
<tr>
<td>LN686</td>
<td>Oral cavity, tongue</td>
<td>324 ± 101</td>
<td>Resistant</td>
</tr>
<tr>
<td>Tu167R2</td>
<td>Oral cavity, floor of mouth</td>
<td>803 ± 189</td>
<td>Resistant</td>
</tr>
<tr>
<td>Tu167R1</td>
<td>Oral cavity, floor of mouth</td>
<td>&gt;1000</td>
<td>Resistant</td>
</tr>
<tr>
<td>Tu138</td>
<td>Oral cavity</td>
<td>&gt;5000</td>
<td>Resistant</td>
</tr>
</tbody>
</table>

#### Table 2: Median effects of Dasatinib and PHA665752 as Single Agents and in Combination

<table>
<thead>
<tr>
<th>Cell line</th>
<th>Single agent, IC$_{50}$</th>
<th>Combination, IC$_{50}$</th>
<th>Combination Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dasatinib (nM)</td>
<td>PHA665752 (μM)</td>
<td>Dasatinib (nM)</td>
</tr>
<tr>
<td>Tu167</td>
<td>45 ± 7.7</td>
<td>6.8 ± 2.1</td>
<td>20 ± 6.6</td>
</tr>
<tr>
<td>TR146</td>
<td>67 ± 2.3</td>
<td>2.6 ± 1.0</td>
<td>27 ± 13</td>
</tr>
<tr>
<td>UMSCC14a</td>
<td>186 ± 15</td>
<td>1.9 ± 0.7</td>
<td>28 ± 18</td>
</tr>
<tr>
<td>Osc19</td>
<td>312 ± 36</td>
<td>8.7 ± 4.9</td>
<td>107 ± 39</td>
</tr>
<tr>
<td>Tu167R2</td>
<td>803 ± 189</td>
<td>22 ± 1.4</td>
<td>268 ± 86</td>
</tr>
<tr>
<td>Tu167R1</td>
<td>&gt;1000</td>
<td>6.5 ± 2.2</td>
<td>316 ± 129</td>
</tr>
<tr>
<td>Tu138</td>
<td>&gt;5000</td>
<td>2.1 ± 0.3</td>
<td>148 ± 19</td>
</tr>
</tbody>
</table>
Data presented as mean ± standard deviation.
Figure Legends

Figure 1. **The effect of SFK inhibition on apoptosis and cell cycle in HNSCC cell lines.** Cells were treated with vehicle control or 100 nM dasatinib for 24 h and analyzed by TUNEL staining (A) or stained with propidium iodide and analyzed by FACS (B). The proportion of apoptotic cells or cells in each cell cycle phase is graphed as percentage of the total. Bars, SD. *P<0.05 (B, for the effect on S-phase) versus vehicle control.

Figure 2. **The effect of SFK inhibition or depletion on c-Met and AKT phosphorylation in a panel of sensitive and resistant HNSCC cell lines.** Nine HNSCC cell lines were incubated with 100 nM dasatinib (A, B, C) for indicated times (A) or for 7 h (B, C, D) and analyzed by Western blotting. (C) Western blots for activated Met (pMet Y1234/1235) from 9 HNSCC cell lines were analyzed by densitometry and normalized to beta-actin and control (i.e., vehicle treated). (E) HNSCC cells were transfected with c-Src–specific siRNA or scrambled siRNA, or mock transfected, and the signaling molecules were analyzed by Western blotting 72 h after transfection.

Figure 3. **c-Met and c-Src interactions as isolated proteins and in intact cells.** (A, B) c-Src or c-Met was immunoprecipitated (IP) from 2 HNSCC cell lines and incubated with 2.5 μM PHA665752 (P) or 100 nM dasatinib (D) or in combination (D/P) as indicated, and kinase activity was measured by the *in vitro* kinase assay. (C) c-Src and c-Met were immunoprecipitated from HNSCC cells that were incubated with 100 nM dasatinib or vehicle control for 7 h. Immunocomplexes were resolved by 11% SDS-PAGE and blotted with c-Src or c-Met antibodies.
Figure 4. Effect of HGF and EGFR inhibition on c-Met activation. (A) HNSCC cells were serum starved and then incubated with 50 ng/ml HGF (5 min) and/or 100 nM dasatinib (7 h) as indicated and signaling molecules were analyzed by Western blotting. (B) HNSCC cells were incubated with 1 μM erlotinib, 100 nM dasatinib, vehicle control, or a combination of both drugs for 7 h and then analyzed by Western blotting.

Figure 5. The combination of SFK and c-Met inhibition resulted in synergistic cytotoxic and signaling effects in vitro and in vivo. Tu138 (A) and Osc19 (B) cells were treated with PHA665752 alone, dasatinib alone, or the 2 agents combined in a fixed ratio at the indicated doses for 72 h. The number of viable cells was determined by MTT assay (O.D., optical density) and expressed as fold control (vehicle alone). (C) Tu138 cells were treated with 100 nM dasatinib, 2 μM PHA665752, or the combination for 24 h and analyzed by TUNEL staining using FACS analysis. (D) HNSCC cells were treated with 100 nM dasatinib, 2.5 μM PHA665752, or both for 7 h and analyzed by Western blotting with the indicated antibodies. (E) Mice bearing orthotopic tongue tumors (Osc19 cells transfected with luciferase) were treated with crizotinib alone, dasatinib alone, or the 2 agents combined and tumor size was measured. P values for the combination at 7 days were 0.002 (vs. control), 0.03 (vs. dasatinib), and 0.01 (vs. crizotinib). P values for the combination at 10 days were 0.007 (vs. control), 0.02 (vs. dasatinib), and 0.05 (vs. crizotinib). (*P<0.05 versus vehicle control).

Figure 6. Depletion of c-Met enhances the cytotoxicity of c-Src depletion. Tu167 and Osc19 cells were transfected with c-Src−specific siRNA (KD, knockdown), c-Met specific siRNA, both, or nonspecific (scrambled) controls. The number of viable cells was estimated 96 h after
transfection by an MTT assay and expressed as fold control (mock transfected). Bars, SD.

*P<0.05 versus vehicle control.

**Supplemental Figures**

**(S1)** Tu167 (sensitive) and Tu167R1 (resistant) cells were treated with increasing concentrations of dasatinib for 7 h and indicated molecules were analyzed by Western blotting.

**(S2)** Eight HNSCC cell lines were analyzed by Western blotting to compare the basal expression and activation of c-Met and c-Src.

**(S3)** Tu167 and Osc19 cells were treated with increasing concentrations of PHA665752, and c-Met activation was analyzed by Western blotting.

**(S4)** (A) Tumor volume was estimated by bioluminescence imaging on day 10 in mice bearing tongue tumors (Osc19 cells transfected with luciferase) treated with vehicle alone, dasatinib, crizotinib, or both agents. *P* value for the combination was 0.02 (vs. control). (B) Representative histology from the primary tumor (arrow, left panel) and nodal metastasis (*, right panel). Tumors were stained with hematoxylin and eosin. Magnification is 200X.

**(S5)** Tumors from mice treated with vehicle alone, dasatinib, crizotinib, or both agents were homogenized and subjected to Western blotting.
(S6) Cells were treated with vehicle control or 100 nM dasatinib, 2.5 μM PHA665752, both agents, or DMSO. Invasion and migration were analyzed and graphed as fold control (DMSO). Bars, SD. *P<0.05 vs. control. The P values for the combination therapy was significant when compared to single agents in all cases.

(S7) Osc19 and Tu167 cell lines were transfected with nonspecific siRNA (scrambled); c-Src−, c-Met−, or both c-Src− and c-Met− specific siRNA; or mock transfected. Cells were subjected to lysis and analyzed by Western blotting to validate efficiency of knockdown.

(S8) Model of c-Src and c-Met interactions in HNSCC. In sensitive cell lines, c-Src mediates cell survival through both c-Met−dependent and −independent pathways. Inhibition of both pathways leads to profound cytotoxicity. In resistant cell lines, c-Src and c-Met do not interact; both pathways contribute to cell survival independently. Inhibition of both pathways leads to synergy but only modest cytotoxicity.

Supplemental Methods

Migration Assay

Cells were grown to confluence on tissue culture dishes, and a single scrape was made in the confluent monolayer using a sterile pipette tip. The monolayer was washed with PBS, and complete medium containing 25 nM dasatinib, 2.5 μM PHA-665752, both agents, or DMSO alone was added. Serial photographs of the same area were taken from 0-16 h. Cell migration
was measured by comparing the size of the wound over time with the original wound size. ImageJ was used to measure the size of the wound at each time point, and all wound sizes were normalized to the original wound size (47).

**Invasion Assay.**

Invasion was measured using a modified Boyden chamber as previously described (10). Briefly, cells to be assayed were placed into the upper compartment. Following attachment, 25 nM dasatinib was added to the cells, and 3T3 conditioned medium was placed into the bottom compartment. The invasive cells were fixed, stained, and counted. In parallel, cells from the same lines were treated identically and stained with trypan blue. The number of cells that had invaded was normalized for effects on cell viability.

**HGF ELISA**

HNSCC tumor cells were grown for 48 h in 10 cm dishes to 70% confluency using serum free DMEM medium in presence or absence of 100 nM dasatinib. Four milliliters of cell culture supernatant were collected and examined for HGF level using Quantikine Human HGF ELISA kit (R&D system) according to the manufacturer’s suggested protocol.
Figure 1A

TUNEL positive (% of total cell population)

- Tu167
- TR146
- PCI-13
- UM-SCC14a
- Osc19
- Tu167R1
- Tu138

Sensitive
Intermediate
Resistant

Control
Dasatinib

* Denotes statistically significant difference compared to control.
Figure 1B

Percent of Total

<table>
<thead>
<tr>
<th>Control</th>
<th>Dasatinib</th>
<th>Control</th>
<th>Dasatinib</th>
<th>Control</th>
<th>Dasatinib</th>
<th>Control</th>
<th>Dasatinib</th>
<th>Control</th>
<th>Dasatinib</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tu167</td>
<td>TR146</td>
<td>PCI-13</td>
<td>UM14a</td>
<td>Osc19</td>
<td>Tu167R1</td>
<td>Tu138</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Sensitive | Intermediate | Resistant

Sub-G0 | G1 | G2/M | S
Fig. 2A

Tu167 cells  Osc19 cells

Dasatinib

- 15 min  + 2 h + 7 h
- 30 min + 4 h + 7 h
- 7 h

pMet (Y1234/1235)
pSFK (Y416)
c-Src
pAKT (S473)
Total AKT
β-Actin
**Fig. 2B**

**Sensitive**
- PCI13
- TR146

**Resistant**
- Osc19
- Tu138

---

**Dasatinib**

<table>
<thead>
<tr>
<th>Protein</th>
<th>Sensitive</th>
<th>Resistant</th>
</tr>
</thead>
<tbody>
<tr>
<td>pMet (Y1234/1235)</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>pMet (Y1234/1235)</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Total c-Met</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>pSFK (Y416)</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>c-Src</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>pAkt (S473)</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Total Akt</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>pPDK1 (S241)</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>β-Actin</td>
<td>-</td>
<td>+</td>
</tr>
</tbody>
</table>

**Darker Exposure**

**Lighter Exposure**
Fig. 2C

Expression of pMet / Beta-actin (Fold Control)

Sensitive    Intermediate    Resistant
Fig. 2D

<table>
<thead>
<tr>
<th></th>
<th>Tu167</th>
<th>Tu167R2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dasatinib</td>
<td>Dasatinib</td>
</tr>
<tr>
<td>Control</td>
<td>50 nM</td>
<td>Control</td>
</tr>
<tr>
<td></td>
<td>100 nM</td>
<td></td>
</tr>
<tr>
<td></td>
<td>200 nM</td>
<td></td>
</tr>
<tr>
<td>pSFK (Y416)</td>
<td></td>
<td>pSFK (Y416)</td>
</tr>
<tr>
<td>pMet (Y1234/1235)</td>
<td></td>
<td>pMet (Y1234/1235)</td>
</tr>
<tr>
<td>Total c-Met</td>
<td></td>
<td>Total c-Met</td>
</tr>
<tr>
<td>pAkt (S473)</td>
<td></td>
<td>pAkt (S473)</td>
</tr>
<tr>
<td>Total Akt</td>
<td></td>
<td>Total Akt</td>
</tr>
<tr>
<td>c-Src</td>
<td></td>
<td>c-Src</td>
</tr>
<tr>
<td>β-Actin</td>
<td></td>
<td>β-Actin</td>
</tr>
</tbody>
</table>
Figure 2E

<table>
<thead>
<tr>
<th></th>
<th>Tu167</th>
<th>PCI13</th>
<th>Osc19</th>
<th>Tu167R2</th>
<th>Tu138</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td><img src="image1.png" alt="Image" /></td>
<td><img src="image2.png" alt="Image" /></td>
<td><img src="image3.png" alt="Image" /></td>
<td><img src="image4.png" alt="Image" /></td>
<td><img src="image5.png" alt="Image" /></td>
</tr>
<tr>
<td>Scrambled</td>
<td><img src="image6.png" alt="Image" /></td>
<td><img src="image7.png" alt="Image" /></td>
<td><img src="image8.png" alt="Image" /></td>
<td><img src="image9.png" alt="Image" /></td>
<td><img src="image10.png" alt="Image" /></td>
</tr>
<tr>
<td>Src KD</td>
<td><img src="image11.png" alt="Image" /></td>
<td><img src="image12.png" alt="Image" /></td>
<td><img src="image13.png" alt="Image" /></td>
<td><img src="image14.png" alt="Image" /></td>
<td><img src="image15.png" alt="Image" /></td>
</tr>
</tbody>
</table>

- pMet (Y1234/1235)
- Total c-Met
- pSFK (Y416)
- c-Src
- Total Yes
- pPDK1 (S241)
- pAkt (S473)
- Total Akt
- β-Actin
### Osc19 cells

<table>
<thead>
<tr>
<th>Drug</th>
<th></th>
<th>D</th>
<th>P</th>
<th></th>
<th>D</th>
<th>P</th>
<th></th>
<th>D</th>
<th>P</th>
<th>D/P</th>
</tr>
</thead>
<tbody>
<tr>
<td>IP c-Met</td>
<td></td>
<td>+</td>
<td>+</td>
<td></td>
<td>+</td>
<td>+</td>
<td></td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>IP c-Src</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
</tbody>
</table>

- **p-Met**
- **p-Src**
Figure 3B

Tu167 cells

<table>
<thead>
<tr>
<th>Drug</th>
<th>-</th>
<th>D</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>IP c-Met</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>IP c-Src</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>D</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>P</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>D/P</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

p-Met

p-Src
Figure 3C

<table>
<thead>
<tr>
<th></th>
<th>Tu167</th>
<th>Osc19</th>
</tr>
</thead>
<tbody>
<tr>
<td>IP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dasatinib</td>
<td>- c-Src + c-Met</td>
<td>- c-Src + c-Met</td>
</tr>
</tbody>
</table>

- c-Met
- c-Src (light exposure)
- c-Src (dark exposure)

<table>
<thead>
<tr>
<th></th>
<th>Tu167R2</th>
<th>Tu138</th>
</tr>
</thead>
<tbody>
<tr>
<td>IP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dasatinib</td>
<td>- c-Src + c-Met</td>
<td>- c-Src + c-Met</td>
</tr>
</tbody>
</table>

- c-Met
- c-Src
Figure 4A

<table>
<thead>
<tr>
<th></th>
<th>Tu167</th>
<th></th>
<th>Osc19</th>
<th></th>
<th>Tu167R2</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>HGF</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Dasatinib</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

- HGF
- pMet (Y1234/1235)
- pMet (Y1365)
- pMet (Y1349)
- pMet (Y1003)
- pSFK (Y416)
- pAkt (S473)
- pPDK1 (S241)
- β-Actin
Figure 4B

Tu167

Control
Dasatinib
Erlotinib
Combination

Tu167R2

Control
Dasatinib
Erlotinib
Combination

Osc19

Control
Dasatinib
Erlotinib
Combination

Tu138

Control
Dasatinib
Erlotinib
Combination

β-Actin
pEGFR (Y1068)
pMet (Y1234/1235)
pSFK (Y416)
pAkt (S473)
pPDK1 (S241)
PdG1
Figure 5A

Tu138 cells

- Dasatinib
- Combination
- PHA665752

O.D. (Fold Control)

Dasatinib (nM)

PHA665752 (uM)
Figure 5B

Osc19 cells

- Dasatinib
- Combination
- PHA665752
Figure 5C

Tu138 cells

TUNEL Positive (% of Total Cells)

Control  Dasatinib  PHA665752  Combination

*
Figure 5D

<table>
<thead>
<tr>
<th></th>
<th>LN686</th>
<th>HN5</th>
<th>UMSSC2</th>
<th>UMSSC47</th>
<th>Osc19</th>
<th>Tu138</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>PHA6655752</td>
<td>Dasatinib</td>
<td>Control</td>
<td>Dasatinib</td>
<td>Combination</td>
<td>PHA6655752</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PHA6655752</td>
<td></td>
<td>Combination</td>
<td>Dasatinib</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PHA6655752</td>
<td></td>
<td>Combination</td>
<td>PHA6655752</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PHA6655752</td>
<td></td>
<td>Combination</td>
<td>PHA6655752</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PHA6655752</td>
<td></td>
<td>Combination</td>
<td>PHA6655752</td>
</tr>
</tbody>
</table>

- pMet (Y1234/1235)
- Total c-Met
- pSFK (Y416)
- c-Src
- pAkt (S473)
- pPDK1 (S241)
- pErbB3 (Y1289)
- β-Actin
Figure 6

Fold control

0 0.2 0.4 0.6 0.8 1 1.2

Control
Scrambled
Tu167 c-Src KD
Tu167 c-Met KD
Tu167 Src/Met KD
Tu167 Control
Scrambled
Osc19 c-Src KD
Osc19 c-Met KD
Osc19 Src/Met KD

* indicates statistical significance.
Fig. S1

- β-Actin
- Total Akt
- pAKT (S473)
- Total Met
- pMet (Y1234/1235)
- pSFK(Y416)

Control
50 nM dasatinib
100 nM dasatinib
200 nM dasatinib

Control
50 nM dasatinib
100 nM dasatinib
200 nM dasatinib

Tu167

Tu167R1
**Fig. S2**

- **Tu167**: sensitive
- **PCI24**: sensitive
- **TR146**: intermediate
- **HN5**: intermediate
- **PCI13**: sensitive
- **UMSCC47**: intermediate
- **UMSCC14a**: intermediate
- **Osc19**: resistant

**β-Actin**, **C-Src**, **pSFK (Y416)**, **Total c-Met**, **pMet(Y1234/1235)**
Figure S3

Tu167
Control
2.5 µM
5 µM
7.5 µM

Osc19
Control
2.5 µM
5 µM
7.5 µM

β-Actin
Total c-Met
pSFK (Y416)
pMet (Y1234/1234)
Figure S4A

![Graph showing average radiance (p/s/cm²/s/×10⁵) for Control, Dasatinib, Crizotinib, and Combination treatments.](image-url)
Figure S5

Vehicle Control

Vehicle Control

Dasatinib

Dasatinib

Crizotinib

Crizotinib

Combination

Combination

β-Actin

pFAK (Y861)

pMet (Y1234/1235)
Figure S7

<table>
<thead>
<tr>
<th></th>
<th>Osc19</th>
<th>Tu167</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scrambled</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Src siRNA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Met siRNA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Src+Met siRNA</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- c-Src
- Total c-Met
- β-Actin
Figure S8

Sensitive Cells

P13K pathway (via AKT or PDK1)

c-Src → Survival

Resistant Cells

c-Src → Survival

EGFR → c-Met

Alternative pathways
Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer

Banibrata Sen, Shao hua Peng, Babita Saigal, et al.

Clin Cancer Res  Published OnlineFirst November 24, 2010.